$CVV
CVD EQUIPMENT CORP Stock $cvv

$cvv Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000149315224011730 Filed on March 28, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023
Revenue	$4.922M	$4.111M	$24.11M
YoY Change	-43.39%	-43.17%	-6.6%
Cost Of Revenue	$4.063M	$4.459M	$19.04M
YoY Change	-35.11%	-14.8%	-0.77%
Gross Profit	$859.0K	-$348.0K	$5.071M
YoY Change	-64.71%	-117.4%	-23.48%
Gross Profit Margin	17.45%	-8.47%	21.03%
Selling, General & Admin	$1.736M	$1.392M	$7.083M
YoY Change	-14.02%	-18.72%	8.24%
% of Gross Profit	202.1%		139.68%
Research & Development	$746.0K	$731.0K	$2.596M
YoY Change	23.92%	43.73%	36.2%
% of Gross Profit	86.85%		51.19%
Depreciation & Amortization	$153.0K	$242.0K	$700.0K
YoY Change	-7.83%	-26.47%	-12.5%
% of Gross Profit	17.81%		13.8%
Operating Expenses	$2.482M	$2.123M	$9.952M
YoY Change	-5.3%	-4.42%	17.78%
Operating Profit	-$1.623M	-$2.471M	-$4.881M
YoY Change	767.91%	1017.29%	167.75%
Interest Expense	$6.000K	$172.0K	$23.00K
YoY Change	0.0%	-28.49%	187.5%
% of Operating Profit
Other Income/Expense, Net	$151.0K	$0.00	$687.0K
YoY Change	1787.5%	-100.0%	4480.0%
Pretax Income	-$1.472M	-$2.299M	-$4.194M
YoY Change	3773.68%	-248.1%	1806.36%
Income Tax		-$25.00K	-$14.00K
% Of Pretax Income
Net Earnings	-$1.472M	-$2.274M	-$4.180M
YoY Change	3580.0%	-246.79%	1766.07%
Net Earnings / Revenue	-29.91%	-55.32%	-17.34%
Basic Earnings Per Share	-$0.22		-$0.62
Diluted Earnings Per Share	-$0.22	-$0.33	-$0.62
COMMON SHARES
Basic Shares Outstanding	6.825M shares	6.825M shares	6.788K shares
Diluted Shares Outstanding	6.809M shares		6.788K shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023
SHORT-TERM ASSETS
Cash & Short-Term Investments	$11.89M	$14.03M	$14.03M
YoY Change	8.11%	-2.37%	-2.37%
Cash & Equivalents	$11.90M	$14.00M	$14.03M
Short-Term Investments
Other Short-Term Assets	$858.0K	$852.0K	$852.0K
YoY Change	26.55%	6.9%	6.9%
Inventory	$4.925M	$4.454M	$4.454M
Prepaid Expenses
Receivables	$2.971M	$1.906M	$3.510M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$23.34M	$22.84M	$22.84M
YoY Change	13.54%	-3.45%	-3.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$12.09M	$12.17M	$12.17M
YoY Change	-3.87%	-3.41%	-3.41%
Goodwill
YoY Change
Intangibles		$9.000K
YoY Change		-92.44%
Long-Term Investments
YoY Change
Other Assets	$18.00K	$9.000K	$9.000K
YoY Change	80.0%	-10.0%	-99.42%
Total Long-Term Assets	$12.11M	$12.18M	$12.18M
YoY Change	-14.92%	-14.52%	-14.52%
TOTAL ASSETS
Total Short-Term Assets	$23.34M	$22.84M	$22.84M
Total Long-Term Assets	$12.11M	$12.18M	$12.18M
Total Assets	$35.44M	$35.03M	$35.03M
YoY Change	1.89%	-7.62%	-7.62%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.798M	$1.203M	$1.203M
YoY Change	25.82%	-17.26%	-17.26%
Accrued Expenses	$1.690M	$1.765M	$1.765M
YoY Change	-20.28%	-31.88%	-31.88%
Deferred Revenue	$6.030M	$4.908M
YoY Change	378.19%	21.43%
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$83.00K	$81.00K	$81.00K
YoY Change	6.41%	5.19%	5.19%
Total Short-Term Liabilities	$10.20M	$8.554M	$8.554M
YoY Change	108.63%	4.78%	4.78%
LONG-TERM LIABILITIES
Long-Term Debt	$247.0K	$268.0K	$268.0K
YoY Change	-24.92%	-23.21%	-23.21%
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities	$247.0K	$268.0K	$268.0K
YoY Change	-24.92%	-23.21%	-23.21%
TOTAL LIABILITIES
Total Short-Term Liabilities	$10.20M	$8.554M	$8.554M
Total Long-Term Liabilities	$247.0K	$268.0K	$268.0K
Total Liabilities	$10.45M	$8.822M	$8.822M
YoY Change	100.21%	3.63%	3.63%
SHAREHOLDERS EQUITY
Retained Earnings	-$4.032M	-$2.560M
YoY Change	-355.19%	-258.02%
Common Stock	$29.03M	$28.76M
YoY Change	3.73%	3.54%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$25.00M	$26.20M	$26.20M
YoY Change
Total Liabilities & Shareholders Equity	$35.44M	$35.03M	$35.03M
YoY Change	1.89%	-7.62%	-7.62%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023
OPERATING ACTIVITIES
Net Income	-$1.472M	-$2.274M	-$4.180M
YoY Change	3580.0%	-246.79%	1766.07%
Depreciation, Depletion And Amortization	$153.0K	$242.0K	$700.0K
YoY Change	-7.83%	-26.47%	-12.5%
Cash From Operating Activities	-$2.043M	-$126.0K	-$206.0K
YoY Change	-37.56%	-104.99%	-206.19%
INVESTING ACTIVITIES
Capital Expenditures	$70.00K	$110.0K	$418.0K
YoY Change	-52.05%	305.46%	-37.14%
Acquisitions
YoY Change
Other Investing Activities		-$3.000K	$597.0K
YoY Change			5870.0%
Cash From Investing Activities	-$70.00K	-$113.0K	-$133.0K
YoY Change	-52.05%	316.51%	-81.21%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net	$19.00K		$77.00K
YoY Change	0.0%		-95.65%
Cash From Financing Activities	-$19.00K	-21.00K	-$1.000K
YoY Change	-135.19%	223.57%	-99.94%
NET CHANGE
Cash From Operating Activities	-$2.043M	-126.0K	-$206.0K
Cash From Investing Activities	-$70.00K	-113.0K	-$133.0K
Cash From Financing Activities	-$19.00K	-21.00K	-$1.000K
Net Change In Cash	-$2.132M	-260.0K	-$340.0K
YoY Change	-36.62%	-110.44%	-85.13%
FREE CASH FLOW
Cash From Operating Activities	-$2.043M	-$126.0K	-$206.0K
Capital Expenditures	$70.00K	$110.0K	$418.0K
Free Cash Flow	-$2.113M	-$236.0K	-$624.0K
YoY Change	-38.18%	-109.46%	32.48%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023	us-gaap	Loans Assumed1 LoansAssumed1		usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods		usd
CY2023	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2022	us-gaap	Incremental Common Shares Attributable To Share Based Payment Arrangements IncrementalCommonSharesAttributableToShareBasedPaymentArrangements		shares
CY2023Q4	CVV	Employee Retention Credit Receivable Noncurrent EmployeeRetentionCreditReceivableNoncurrent		usd
CY2022Q4	CVV	Deposits From Purchaser Of Mesoscribe Assets DepositsFromPurchaserOfMesoscribeAssets		usd
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023	CVV	Employee Retention Tax Credits Income EmployeeRetentionTaxCreditsIncome		usd
CY2022	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness		usd
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges		usd
CY2023	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable		usd
CY2022	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation		usd
CY2022	CVV	Proceeds From Deposits From Purchaser Of Mesoscribe Assets ProceedsFromDepositsFromPurchaserOfMesoscribeAssets		usd
CY2023	CVV	Payments For Capitalized Patent Costs PaymentsForCapitalizedPatentCosts		usd
CY2023	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment		usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
CY2023	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit		usd
CY2023	CVV	Effective Income Tax Rate Reconciliation Us Taxation Of Foreign Operations Amount EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperationsAmount		usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate		usd
CY2022	us-gaap	Income Tax Reconciliation Disposition Of Business IncomeTaxReconciliationDispositionOfBusiness		usd
CY2023Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2022	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets		usd
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	48002094	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6824511	shares
CY2023	dei	Auditor Firm AuditorFirmId	688
CY2023	dei	Auditor Name AuditorName	Marcum LLP
CY2023	dei	Auditor Location AuditorLocation	Melville, NY
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14025000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14365000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	1906000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3788000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1604000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2170000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4454000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2538000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	852000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	797000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	22841000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	23658000	usd
CY2022Q4	CVV	Employee Retention Credit Receivable Noncurrent EmployeeRetentionCreditReceivableNoncurrent	1529000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12166000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12596000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	9000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	119000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	9000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	10000	usd
CY2023Q4	us-gaap	Assets Assets	35025000	usd
CY2022Q4	us-gaap	Assets Assets	37912000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1203000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1454000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1765000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2591000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	81000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	77000	usd
CY2023Q4	CVV	Deposits From Purchaser Of Mesoscribe Assets DepositsFromPurchaserOfMesoscribeAssets	597000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4908000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4042000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8554000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	8164000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	268000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	349000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	8822000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	8513000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6824511	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6824511	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	6760938	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	6760938	shares
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	68000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	67000	usd
CY2023Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	28695000	usd
CY2022Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	27712000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-2560000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	1620000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	26203000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	29399000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	35025000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37912000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24109000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25813000	usd
CY2023	us-gaap	Cost Of Revenue CostOfRevenue	19038000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	19186000	usd
CY2023	us-gaap	Gross Profit GrossProfit	5071000	usd
CY2022	us-gaap	Gross Profit GrossProfit	6627000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2596000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1906000	usd
CY2023	us-gaap	Selling Expense SellingExpense	1632000	usd
CY2022	us-gaap	Selling Expense SellingExpense	1216000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5451000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5328000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	9952000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4881000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1823000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	577000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	162000	usd
CY2023	us-gaap	Interest Expense InterestExpense	23000	usd
CY2022	us-gaap	Interest Expense InterestExpense	8000	usd
CY2022	CVV	Employee Retention Tax Credits Income EmployeeRetentionTaxCreditsIncome	1529000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	42000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-95000	usd
CY2023	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	91000	usd
CY2022	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	15000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	687000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	1603000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4194000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-220000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-14000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4180000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-224000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.62
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.03
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.62
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.03
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6788	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6734	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6788	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6734	shares
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	29188000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-224000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	435000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	29399000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	29399000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4180000	usd
CY2023	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	908000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	76000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	26203000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	26203000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-4180000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-224000	usd
CY2023	us-gaap	Gain Loss On Sale Of Business GainLossOnSaleOfBusiness	-162000	usd
CY2023	us-gaap	Asset Impairment Charges AssetImpairmentCharges	111000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	908000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	435000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	792000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	867000	usd
CY2023	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1841000	usd
CY2022	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	2342000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-566000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Asset IncreaseDecreaseInContractWithCustomerAsset	-368000	usd
CY2023	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1921000	usd
CY2022	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1313000	usd
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	-716000	usd
CY2023	CVV	Increase Decrease In Employee Retention Credit Receivable IncreaseDecreaseInEmployeeRetentionCreditReceivable	-1529000	usd
CY2022	CVV	Increase Decrease In Employee Retention Credit Receivable IncreaseDecreaseInEmployeeRetentionCreditReceivable	1529000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	47000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	301000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-154000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	293000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-679000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	832000	usd
CY2023	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	866000	usd
CY2022	us-gaap	Increase Decrease In Contract With Customer Liability IncreaseDecreaseInContractWithCustomerLiability	2392000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-206000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	194000	usd
CY2023	us-gaap	Cash Divested From Deconsolidation CashDivestedFromDeconsolidation	312000	usd
CY2023	CVV	Proceeds From Deposits From Purchaser Of Mesoscribe Assets ProceedsFromDepositsFromPurchaserOfMesoscribeAssets	597000	usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	418000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	665000	usd
CY2022	CVV	Payments For Capitalized Patent Costs PaymentsForCapitalizedPatentCosts	53000	usd
CY2022	us-gaap	Proceeds From Sale Of Machinery And Equipment ProceedsFromSaleOfMachineryAndEquipment	10000	usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-133000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-708000	usd
CY2023	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	76000	usd
CY2023	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	77000	usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1772000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1772000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-340000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2286000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14365000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	16651000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14025000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	14365000	usd
CY2023	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	8000	usd
CY2022	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	1000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	24000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	8000	usd
CY2022	us-gaap	Loans Assumed1 LoansAssumed1	432000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14000000.0	usd
CY2023	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_848_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zZzI82UYxsFa" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white"><span style="text-decoration: underline"><span id="xdx_868_zpFOVRJqSdvk">Reclassifications</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In addition, certain reclassifications have been made to the prior period consolidated financial statements to conform to the current period presentation. These reclassifications had no effect on net (loss).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_841_eus-gaap--UseOfEstimates_zVyWiev3tKj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zquej73hHBo1">Use of Estimates</span></span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company’s significant estimates are the accounting for certain items such as revenues on long-term contracts recognized on the input method, valuation of inventories at the lower of cost or net realizable value; allowance for credit losses; valuation allowances for deferred tax assets, estimated lives and impairment considerations of long-lived assets and valuation of stock-based compensation.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0	usd
CY2022	us-gaap	Capitalized Contract Cost Impairment Loss CapitalizedContractCostImpairmentLoss	0	usd
CY2022	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	25813000	usd
CY2023	us-gaap	Standard Product Warranty Description StandardProductWarrantyDescription	The Company typically provides standard warranty coverage on its systems for one year from the date of final acceptance or fifteen months from the date of shipment by providing labor and parts necessary to repair the systems during the warranty period
CY2023	us-gaap	Income Tax Examination Likelihood Of Unfavorable Settlement IncomeTaxExaminationLikelihoodOfUnfavorableSettlement	tax benefit that is more than 50% likely to be realized upon ultimate settlement
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14000000.0	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	14400000	usd
CY2023Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	12100000	usd
CY2022Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	11700000	usd
CY2023Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1500000	usd
CY2022Q4	us-gaap	Cash Uninsured Amount CashUninsuredAmount	1500000	usd
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_843_eus-gaap--ConcentrationRiskCreditRisk_zgwzpO8pVhQ2" style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"><span style="text-decoration: underline"><span id="xdx_86C_zu2pmibBOxs9">Concentration of Credit Risk</span></span></span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font: normal 10pt Times New Roman, Times, Serif"> </span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font: normal 10pt Times New Roman, Times, Serif">Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash, cash equivalents, and accounts receivable. The Company places its cash equivalents with financial institutions and invests its excess cash primarily in treasury bills, certificates of deposit or deposit accounts. The Company has established guidelines relative to credit ratings and maturities that seek to maintain stability and liquidity. </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company routinely assesses the financial strength of its customers<i>.</i> In accordance with the “expected credit loss” model, the carrying amount of accounts receivable is reduced by a valuation allowance that reflects the best estimate of the amounts the Company does not expect to collect. In addition to reviewing delinquent accounts receivable, the Company consider many factors in estimating our reserve, including types of customers and their credit worthiness, experience and historical data adjusted for current conditions and reasonable supportable forecasts<i>. </i>The Company records an allowance for credit losses based upon a specific review of all significant outstanding invoices. For those invoices not specifically reviewed, provisions are provided based upon the collection history, current economic trends and reasonable supportable forecasts.</span></p> <p style="font: italic 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The Company has accounts receivables from certain customers that exceed <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerMember_zA104u7YpLSk" title="Concentration risk percentage">10</span>%. As of December 31, 2023, the accounts receivable balance includes amounts from three customers that represented <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_zPtP2fFbXBq5" title="Concentration risk percentage">37.6</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zRZvs7SwCpme" title="Concentration risk percentage">13.0</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20231231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerThreeMember_zbnpJWf01vvk" title="Concentration risk percentage">12.8</span>% of total accounts receivable, and as of December 31, 2022, two customers that represented <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerOneMember_z1p2BHOaPDO8" title="Concentration risk percentage">35.7</span>% and <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20220101__20221231__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--CustomerTwoMember_zzdbXFbbKSXd" title="Concentration risk percentage">30.3</span>% of total accounts receivable.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>CVD EQUIPMENT CORPORATION AND SUBSIDIARIES</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">December 31, 2023 and 2022</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Note 2 - Summary of Significant Accounting Policies (continued)</b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accounts receivable is presented net of an allowance for credit losses of $<span id="xdx_90C_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20231231_zwJ2hxRKgXZd" title="Allowance for credit loss"><span id="xdx_900_eus-gaap--AllowanceForDoubtfulAccountsReceivableCurrent_iI_c20221231_zIbR2HhUcnSg" title="Allowance for credit loss">36,000</span></span> as of both December 31, 2023 and 2022. <span style="background-color: white">The allowance is based on prior experience and management’s evaluation of future economic conditions. Measurement of credit losses requires consideration of historical loss experience, including the need to adjust for changing business conditions, and judgments about the probable effects of relevant observable data, including present economic conditions such as delinquency rates and the financial health of specific customers. Future changes to the estimated allowance for doubtful accounts could be material to our results of operations and financial condition.</span></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	36000	usd
CY2022Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	36000	usd
CY2023	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	24109000	usd
CY2023Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	16300000	usd
CY2023Q4	CVV	Costs Incurred On Uncompleted Contracts CostsIncurredOnUncompletedContracts	9500000	usd
CY2022Q4	CVV	Costs Incurred On Uncompleted Contracts CostsIncurredOnUncompletedContracts	14390000	usd
CY2023Q4	CVV	Estimated Earnings EstimatedEarnings	5083000	usd
CY2022Q4	CVV	Estimated Earnings EstimatedEarnings	10926000	usd
CY2023Q4	CVV	Costs And Estimated Earnings On Uncompleted Contracts CostsAndEstimatedEarningsOnUncompletedContracts	14583000	usd
CY2022Q4	CVV	Costs And Estimated Earnings On Uncompleted Contracts CostsAndEstimatedEarningsOnUncompletedContracts	25316000	usd
CY2023Q4	CVV	Billings To Date BillingsToDate	17553000	usd
CY2022Q4	CVV	Billings To Date BillingsToDate	26925000	usd
CY2023Q4	CVV	Net Cost In Excess Of Billings NetCostInExcessOfBillings	-2970000	usd
CY2022Q4	CVV	Net Cost In Excess Of Billings NetCostInExcessOfBillings	-1609000	usd
CY2023Q4	CVV	Deferred Revenues Related To Contracts DeferredRevenuesRelatedToContracts	-334000	usd
CY2022Q4	CVV	Deferred Revenues Related To Contracts DeferredRevenuesRelatedToContracts	-263000	usd
CY2023Q4	CVV	Contract Liability In Excess Of Contract Assets ContractLiabilityInExcessOfContractAssets	-3304000	usd
CY2022Q4	CVV	Contract Liability In Excess Of Contract Assets ContractLiabilityInExcessOfContractAssets	-1872000	usd
CY2023Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	1604000	usd
CY2022Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2170000	usd
CY2023Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4908000	usd
CY2022Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	4042000	usd
CY2023	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	3700000	usd
CY2022	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	1700000	usd
CY2021Q4	us-gaap	Contract With Customer Asset Net Current ContractWithCustomerAssetNetCurrent	2500000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2351000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	2165000	usd
CY2023Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1248000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	373000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	855000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	4454000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	2538000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22721000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	22572000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	10555000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	9976000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12166000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	12596000	usd
CY2023	us-gaap	Depreciation Depreciation	700000	usd
CY2022	us-gaap	Depreciation Depreciation	800000	usd
CY2023	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2022	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	100000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	1000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	1000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	1000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	1000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	1000	usd
CY2023Q4	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	1000	usd
CY2023Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	358000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	995000	usd
CY2023Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	729000	usd
CY2022Q4	us-gaap	Accrued Vacation Current AccruedVacationCurrent	905000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	678000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	691000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1765000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2591000	usd
CY2023	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	8000	usd
CY2023Q4	us-gaap	Debt Instrument Interest Rate Stated Percentage DebtInstrumentInterestRateStatedPercentage	0.06	pure
CY2023Q4	us-gaap	Loans Payable LoansPayable	349000	usd
CY2022Q4	us-gaap	Loans Payable LoansPayable	426000	usd
CY2023Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	81000	usd
CY2022Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	77000	usd
CY2023Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	268000	usd
CY2022Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	349000	usd
CY2022Q3	CVV	Loan To Fund Acquisition Of Machinery Equipment LoanToFundAcquisitionOfMachineryEquipment	400000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	81000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	87000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	92000	usd
CY2023Q4	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	89000	usd
CY2023Q4	us-gaap	Long Term Debt LongTermDebt	349000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6788	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6734	shares
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6788	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6734	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	846875	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	335375	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	673000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	265000	shares
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	846875	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	673000	shares
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-4073000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-596000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	-121000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	376000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4194000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-220000	usd
CY2023	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	-16000	usd
CY2022	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	1000	usd
CY2023	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2000	usd
CY2022	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	3000	usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	-14000	usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	4000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-14000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
CY2023	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.21	pure
CY2023	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-881000	usd
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-46000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	688000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	-33000	usd
CY2023	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	21000	usd
CY2022	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	84000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	4000	usd
CY2022	CVV	Effective Income Tax Rate Reconciliation Us Taxation Of Foreign Operations Amount EffectiveIncomeTaxRateReconciliationUSTaxationOfForeignOperationsAmount	80000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	75000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	55000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	10000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	37000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	62000	usd
CY2023	us-gaap	Income Tax Reconciliation Disposition Of Business IncomeTaxReconciliationDispositionOfBusiness	193000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	4000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-102000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-14000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	849000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	482000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1863000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Credit Carryforwards Research DeferredTaxAssetsTaxCreditCarryforwardsResearch	1723000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	113000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Employee Compensation DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeCompensation	10000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	153000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Compensated Absences DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsCompensatedAbsences	174000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	38000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	27000	usd
CY2023Q4	CVV	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	759000	usd
CY2022Q4	CVV	Deferred Tax Assets Capitalized Research And Development DeferredTaxAssetsCapitalizedResearchAndDevelopment	356000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	303000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	263000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	4078000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3035000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	3646000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2957000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	432000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	78000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	365000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	11000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	67000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities Prepaid Expenses DeferredTaxLiabilitiesPrepaidExpenses	67000	usd
CY2023	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	700000	usd
CY2023Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2022Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0	usd
CY2023	us-gaap	Income Tax Examination Description IncomeTaxExaminationDescription	The federal tax years open to examination are 2020 to 2023. The Company’s state and local tax years that are open to tax examination are generally 2019 to 2023
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	6.57
CY2023	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	35625	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	4.53
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	846875	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.20
CY2022	CVV	Increase Decrease In Employee Retention Credit Receivable IncreaseDecreaseInEmployeeRetentionCreditReceivable	1500000	usd
CY2022Q4	CVV	Employee Retention Credit Receivable Noncurrent EmployeeRetentionCreditReceivableNoncurrent	1500000	usd
CY2022	CVV	Employee Retention Tax Credits Income EmployeeRetentionTaxCreditsIncome	1500000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	900000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	400000	usd
CY2023	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	908000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	435000	usd
CY2023Q4	us-gaap	Share Price SharePrice	14.02
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	14.02
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	0.72	pure
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0339	pure
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P6Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	846875	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	618500	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	11.26
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	198500	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	5.04
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	144000	shares
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	11.72
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	673000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.70
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	254000	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	14.02
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	44500	shares
CY2022Q3	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50	pure
CY2022Q3	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent DefinedContributionPlanEmployerMatchingContributionPercent	0.06	pure
CY2023	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	243000	usd
CY2022	us-gaap	Defined Contribution Plan Cost Recognized DefinedContributionPlanCostRecognized	90000	usd
CY2023	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2022	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0	usd
CY2023	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	3	segment
CY2023Q4	us-gaap	Assets Assets	35025000	usd
CY2023	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	24109000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-4881000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4194000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	792000	usd
CY2023	us-gaap	Segment Expenditure Addition To Long Lived Assets SegmentExpenditureAdditionToLongLivedAssets	418000	usd
CY2022Q4	us-gaap	Assets Assets	37912000	usd
CY2022	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	25813000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-1823000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-220000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	867000	usd
CY2022Q4	CVV	Loan To Fund Acquisition Of Machinery Equipment LoanToFundAcquisitionOfMachineryEquipment	400000	usd

Files In Submission

Name	View Source	Status
0001493152-24-011730-index-headers.html	Edgar Link	pending
0001493152-24-011730-index.html	Edgar Link	pending
0001493152-24-011730.txt	Edgar Link	pending
0001493152-24-011730-xbrl.zip	Edgar Link	pending
cvv-20231231.xsd	Edgar Link	pending
ex-97.htm	Edgar Link	pending
ex21-1.htm	Edgar Link	pending
cvv-20231231_cal.xml	Edgar Link	unprocessable
ex23-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
ex97_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-k.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
form10-k_htm.xml	Edgar Link	completed
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
cvv-20231231_pre.xml	Edgar Link	unprocessable
cvv-20231231_def.xml	Edgar Link	unprocessable
cvv-20231231_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVV
CVD EQUIPMENT CORP Stock $cvv

2024 Q1 Form 10-K Financial Statement

#000149315224011730 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVV CVD EQUIPMENT CORP Stock $cvv

2024 Q1 Form 10-K Financial Statement

#000149315224011730 Filed on March 28, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVV
CVD EQUIPMENT CORP Stock $cvv